Argus Upgrades Boston Scientific, Sees Market Share Gains And Strong Growth Ahead

Boston Scientific Corporation BSX shares are trading marginally above its peer multiple, which Argus’ David Toung believes still makes the stock attractive, given the company’s robust growth prospects.

Toung upgraded the rating on Boston Scientific from Hold to Buy with a price target of $33.

Strong Sales

The company reported strong Q2:16 sales, with more than 10 percent growth across five product segments.

The analyst pointed out that Boston Scientific had “recently launched a new MRI-compatible pacemaker, which is helping it to gain share in the pacing market. We think these gains are sustainable.”

Related Link: 13F From Paulson & Co. Shows Increased Stakes In Boston Scientific, Rite Aid, Office Depot, Facebook

Guidance And Estimates Raised

The company raised its 2016 guidance, increasing the sales guidance from $8.075–$8.225 billion to $8.270–$8.370 billion and the adjusted EPS guidance from $1.06–$1.10 to $1.07–$1.11.

Following the revised guidance the EPS estimates for 2016 and 2017 have been raised from $1.08 to $1.11 and from $1.20 to $1.27, respectively.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorEarningsLong IdeasUpgradesPrice TargetAnalyst RatingsTrading IdeasArgusDavid Toung
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!